Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 8Active not recruiting 6Recruiting 5Terminated 4Withdrawn 1Unknown 1No longer available 1

Sponsor Class

INDUSTRY 6NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 1Lung Neoplasms 1KRAS p.G12C Mutant Advanced Solid Tumors 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Advanced Solid Tumors 1

Interventions

pembrolizumab 184Carboplatin 132Cisplatin 102Paclitaxel 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 67Docetaxel 55atezolizumab 51Cyclophosphamide 49Bevacizumab 49Dexamethasone 45Capecitabine 45Oxaliplatin 42130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 37Prednisone 32osimertinib 31olaparib 29venetoclax 28fludarabine 28Leucovorin 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × sotorasib × Clear all
NCT06333951 2026-05-28

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Amgen

Phase 1 Active not recruiting
49 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04303780 2026-04-30

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Amgen

Phase 3 Active not recruiting
345 enrolled 11 charts
Thoracic

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT06497556 2026-04-20

Krascendo 1

Hoffmann-La Roche

Phase 3 Active not recruiting
338 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05074810 2026-01-12

RAMP203

Verastem, Inc.

Phase 1/2 Active not recruiting
153 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡